According to the latest analysis provided by the company, the effective rate of Pfizer/BioNTech COVID-19 filtered vaccine is 95%. Bionic
“An amazing science teacher”. Pfizer and BioNTech are updating promising COVID-19 vaccine results. The COVID-19 scientific report was supported by the Pulitzer Center and the Heising Simmons Foundation.
In order not to allow competitors to stand out in similar products, Pfizer and BioNTech today provided the latest information on the success of the previously announced COVID-19 vaccine. Based on the final analysis of the study of 43,000 people, the US pharmaceutical giant and its German biotechnology partner reported 95% effectiveness of the vaccine candidate. Don’t worry if older people do not respond to the vaccine. The two companies said in a press release that for people 65 years of age or older, the efficacy has only dropped to 94%.
Contrary to the mysterious initial report last week that their vaccine is more than 90% effective, Pfizer and BioNTech now provide more specific data because this study has completed enough COVID-19 cases. In total, the trial included 162 confirmed asymptomatic COVID-19 cases in the placebo group, while eight of those received two doses of the scheduled dose of the vaccine. The two companies stated that the effectiveness measured 7 days after the second vaccination is the same across races and races, although subgroup analysis is always uncertain.
Of the ten people who had severe COVID-19 cases during the trial, nine received a placebo, which shows that even if the vaccine cannot prevent symptoms of the disease, it still provides strong protection against serious injuries. These companies reported that no serious side effects were observed, although 3.7% of vaccinators reported feeling tired after the injection.
The results are almost the same as the preliminary results reported by Moderna in the “Continuing Efficacy Trial” on November 16. Both your vaccine and Pfizer/BioNTech filters contain messenger RNA (mRNA), which encodes the surface protein of SARS-CoV-2 (the virus that causes COVID-19). The strategy is now: to date, drugs made using mRNA have not been approved for widespread use in humans.
The collaboration between Pfizer and BioNTech stated that it will apply to the US Food and Drug Administration for emergency use of the vaccine “within a few days.” If modern history repeats itself, Moderna will do so in about a week. The FDA said it will convene its independent vaccine advisory committee to review any U.S. applications for COVID-19. Officials from the agency told ScienceInsider that the first meeting may be held on December 9.
Trudy Lang, head of Oxford University’s Global Health Network, said: “This is a wonderful and reassuring situation that we have discovered. The transition is a milestone in the scientific community”.
As the coronavirus (COVID-19) epidemic continues to severely affect the industry, the prospects for the recovery of the tourism economy remain highly uncertain.
The result of 2020 is expected to be a decline of about 80% in the international tourism economy (lower than previous estimates), while domestic tourism will lead the recovery in the short term. Governments have taken impressive immediate measures to restore and revitalize the sector while protecting jobs and companies. Considering the long-term impact of the crisis, countries are also committed to formulating measures to build a more resilient tourism economy in the post-COVID-19 environment. This includes staying ahead of the digital curve, supporting low-carbon transitions, and rethinking the future of tourism.
It can be said that 2020 has been one of the most memorable years in the travel vaccine industry. As the coronavirus pandemic has caused widespread economic blockades, movement restrictions, travel bans and changes in consumer behaviour, the travel vaccine industry has also played a role in the global economic downturn.
In 2019, the global travel vaccine market was valued at US$5.2 billion, and the expected growth rate from 2020 to 2027 is 8.7%. Although industry insiders still expect the market size to grow moderately during the forecast period, the impact of the coronavirus pandemic may exclude it.
Travel vaccines are vaccines that travellers obtain before visiting certain regions or countries. These vaccines are given to protect travellers from certain infectious diseases and to prevent the spread of infectious diseases internationally to regions or countries where the disease is less common. The increase in global travel, the rapid development of technology and the increase in life-threatening infectious diseases are the main driving forces of the travel vaccine market.
The main factor driving the global travel vaccine market is travel requirements, which require travellers from endemic areas to undergo mandatory vaccination. For example, the Ministry of Health of the Kingdom of Saudi Arabia requires all travellers entering Ha and Umra from areas that are highly susceptible to polio, yellow fever and meningococcal meningitis to produce vaccination certificates to prove, they have received these vaccines.
Other countries and regions such as the United Arab Emirates, Solomon Islands, and Saudi Arabia require travellers from countries at risk of yellow fever transmission (such as Angola, Cameroon, Central African Republic and Chad) to request yellow fever vaccination.
In the past decade, travel dynamics have boosted the travel vaccine business of major companies such as Sanofi Pasteur, Novartis and Pfizer. GlaxoSmithKline Pharmaceuticals Ltd (GlaxoSmithKline Pharmaceuticals Ltd) continues to advance through the growth of its activities. Tourists during this time. However, the coronavirus pandemic has brought many challenges and opportunities that will affect market expectations.
On the one hand, due to global travel restrictions, the supply of vaccines has been greatly reduced. On the other hand, the production and supply of coronavirus vaccines may also increase.
The economic downturn has affected the production capacity of global manufacturers, and the crash caused by the aviation pandemic has weakened the logistics of vaccine supply and availability.
The United Nations Children’s International Emergency Fund (UNICEF) poin
ted out in a recent report that many countries have suspended immunization programs due to a shortage of vaccine supplies. Some countries in Eastern and Southern Africa, Western and Central Africa, and East Asia report very low inventory levels of measles, hepatitis B, human papillomavirus, rotavirus and pneumococcal vaccines.
The Vice President of Punjab University of Health Sciences, Dr Javid Akram, said on Wednesday that the coronavirus vaccine should be obtained in Pakistan “within six to eight weeks.”
In an interview with Earth News, Dr Akram said that his institute has tested the Chinese vaccine on more than 3,000 people across the country in its ongoing Phase 3-B clinical trial.
He added that the antibody response of vaccinated individuals is promising.
After 28 days, we vaccinated people and tested the virus. Dr Akram said: “The trial is being carried out successfully and a vaccine to prevent the spread of COVID-19 should be provided in Pakistan within six to eight weeks.”
He explained how the vaccine works and said that if 35% of the population is vaccinated, the epidemic will be controlled.
Dr Javid Akram said: “To know the effectiveness of the vaccine, it is important to experiment with our people.” “Trials in the United States and China may be invalid in Pakistan.”
On Tuesday, Prime Minister Imran Khan’s National Science and Technology Task Force, Dr Atta-ur-Rehman, stated that Pakistan is testing two Chinese vaccines, which he said are yielding positive results.
Dr Rahman said: “The Chinese vaccine produced by Sinopharm is in the third phase of clinical trials and has shown good results in many countries, but it has not highlighted its success like Pfizer.”
He added that the experiment was carried out at the International Chemical and Biological Sciences Center of Karachi University and Indus Hospital.
The person in charge of the working group said that the Chinese Medicine Group agreed to provide the vaccine to Pakistan at a “reasonable price”, adding that the third phase of clinical trials of another Chinese vaccine is currently underway at the National Institutes of Health.
Dr Rahman said: “Unlike Pfizer vaccines, Chinese vaccines can be transported at room temperature and do not need to be kept at -80 degrees Celsius. They will be more suitable for Pakistan and other third world countries.”
This may mean that countries such as Australia, Canada, the United Kingdom and the United States may start vaccinating their populations in 2021, but again, this will take time. As almost no one wants to be vaccinated, travel will continue to be severely disrupted by 2021.
Rich countries can make POVR mandatory as the only permit condition for entry into the tourism industry, but this possibility is extremely unlikely until the vaccine is widely available to the public.
By 2021, various types of COVID-19 entry requirements are in place, and they will continue to change throughout the year.
As more countries adopt POVR as an alternative to COVID-19 PCR testing or isolation, the vaccine may make things easier for some travellers in the second half of 2021.
The entire global population is unlikely to be vaccinated in 2021 and obtain a globally recognized certificate of vaccination. Compared with now, travel will not be easier, and it may be more chaotic. Pakistan Tourism Industry prospers as the COVID Vaccine reaches to masses.